SCHEMBL7717092

SCHEMBL7717092

CCC(C#N)c1ccc(CBr)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 10/20 0.46
ESR1 P03372 9/20 0.46
ALDH1A1 P00352 2/20 0.46
CYP1A2 P05177 2/20 0.46
MEN1 O00255 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
KMT2A Q03164 1/20 0.46
TSHR P16473 2/20 0.33
TRPA1 O75762 1/20 0.33
NEK1 Q96PY6 1/20 0.33
CYP2A6 P11509 1/20 0.32
MAPK1 P28482 1/20 0.31
ATM Q13315 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
CYP1A1 P04798 1/20 0.30
CYP1B1 Q16678 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7717084 0.85 ESR2 (0.43) ESR2ESR1ALDH1A1CYP1A2MEN1
SCHEMBL10518435 0.82 ESR2 (0.41) ESR2ESR1ALDH1A1CYP1A2MEN1
SCHEMBL7716790 0.81 ESR2 (0.43) ESR2ESR1ALDH1A1CYP1A2MEN1
SCHEMBL27987125 0.81 ESR2 (0.46) ESR2ESR1ALDH1A1CYP1A2MEN1
SCHEMBL8505408 0.80 ESR2 (0.40) ESR2ESR1ALDH1A1CYP1A2MEN1
SCHEMBL29061978 0.80 ESR2 (0.40) ESR2ESR1ALDH1A1CYP1A2MEN1
SCHEMBL11183267 0.79 ESR2 (0.53) ESR2ESR1ALDH1A1CYP1A2MEN1
SCHEMBL7711209 0.79 CYP1A2 (0.34) ESR2ESR1ALDH1A1CYP1A2MEN1
SCHEMBL954801 0.78 ALDH1A1 (0.41) ESR2ESR1ALDH1A1CYP1A2MEN1
SCHEMBL29061985 0.78 ALDH1A1 (0.41) ESR2ESR1ALDH1A1CYP1A2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6376512-B1 FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-23 US disclosed
US-5059610-A QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1991-10-22 US disclosed
US-4920132-A Quinoline derivatives and use thereof as antagonists of leukotriene D4 RORER PHARMACEUTICAL CORP. (US) 1990-04-24 US disclosed
WO-1989004305-A1 QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 RORER INTERNATIONAL (OVERSEAS) INC. (US) 1989-05-18 WO disclosed